
A real-world study in China finds that nearly 29% of COPD patients on triple inhaled therapy remain highly symptomatic with frequent exacerbations. These patients, often older and with more severe symptoms, show only partial disease control. Findings highlight urgent unmet needs and the call for novel therapies and better guideline-based management.
Like
Save
Share